Key Takeaways
- ARV washout drove an operating loss in Q4: ARV revenue collapsed to just ₹6 crore (vs. >₹200 crore in preceding quarters) as global agency bidding paused, triggering a sharp inventory correction and a quarterly operating loss.
- Ibuprofen ramp is the FY23 story: Commercial production began, domestic sales started, and management targets 80–85% capacity utilization by FY23 end, with peak revenue potential of ₹450–500 crores at full scale.
- Sitagliptin is the next big swing: European patent expiry in mid-2022 and U.S. in 2024; management is being "very aggressive on pricing" but declines to commit on market share, calling the launch outcome the product's "fate."
- Minimum 25% revenue growth guided for FY23: Driven by Ibuprofen, Sitagliptin, other patent-expiry products, and ARV recovery; EBITDA target above 22% despite expected gross margin compression from higher-volume products.
- What to watch next quarter: Whether ARV revenue actually normalizes by H1 FY23 as guided, the pace of Ibuprofen customer conversion against incumbents, and the CEP approval timeline for regulated market access.
ARV: The Q4 Collapse & Recovery Bet
- What broke: Customer off-take on CMO arrangements fell sharply in H2 FY22 because the global agencies' bidding process was delayed, triggering a severe inventory correction at the customer end. Q4 was a near-complete washout with minimal product uptake.
- The operating loss mechanics: Fixed expenditure (power, fuel, salaries, manufacturing overhead) could not be reduced in line with the top-line drop, and the company used the slowdown to perform plant maintenance, which further increased operating expenditure. The loss was quarterly, not full-year.
- Recovery visibility exists: Some ARV bids have already been awarded to SMS, giving management confidence that revenue will return to earlier levels by the first half of FY23. The H2 FY22 drop is characterized as a one-off with transient issues.
- Pricing opacity: Management declined to answer whether destructive bidding in ARV tenders has stopped, stating it is a B2B supplier with no visibility into the prices at which its partners bid.
Potluri: "However, we firmly believe that second half of FY22 was a one-off in terms of ARV demand, and the issues are transient in nature."
Ibuprofen: The Ramp, The Risk & The Revenue
- Where things stand: Commercial production commenced at the Vizag facility in FY22, and the company has started selling good quantities in the domestic market over the last two to three months. A CEP filing is awaiting approval (expected in the next one or two months), and a US-DMF was filed earlier.
- The utilization target: Management expects to reach 80–85% of installed capacity by FY23 end, with FY24 being the first full year reflecting Ibuprofen revenue at that utilization level. Peak revenue at full-scale operations is estimated at roughly ₹450–500 crores.
- Capacity expansion is coming: A decision is pending between CAPEX and debottlenecking existing equipment, targeting 600–700 tonnes from the current 500 without major CAPEX. Expansion will definitely happen by FY23 end.
- The conversion challenge: Management is explicit that converting customers from their existing sources is "definitely going to be a difficult job" and not a cakewalk, though it is betting on its expertise and customer willingness to give SMS a chance.
- Contribution was nominal in FY22: Ibuprofen added very little to the top line for the year just ended, so the ramp is almost entirely a forward-looking story.
Potluri: "We believe that the demand and pricing of Ibuprofen has almost bottomed out and going forward we should expect a significant rebound."
Sitagliptin & The Patent-Expiry Pipeline
- Sitagliptin timing: European patent expiry is in July 2022; U.S. expiry is in 2024 with an exclusivity period. The product is a joint venture with partner Chemo, and SMS is being very aggressive on pricing.
- Market size is a moving target: At peak, the API market is estimated at ₹400–500 crores, but that assumes 93–94% price erosion. If erosion reaches 98%, the market shrinks to ₹300 crores. Management declines to commit on market share pre-launch, stating that post-launch capture "decides the fate of the product."
- Other pipeline products: R&D is working on 2–3 other major volume-based products (confidential), expected to materialize in the next one-year span, using existing capacities with only minor CAPEX.
- No major CAPEX for two years: The strategy is to consolidate Ibuprofen, ARV, Sitagliptin, and other coming products; expansion decisions will be revisited only after reaching ~85% capacity utilization.
Potluri: "post-launch, the amount of market share that you will be able to capture actually decides the fate of the product going forward."
COVID-19 Opportunistic Products
- Licenses secured, no revenue budgeted: SMS received non-exclusive MPP licenses for Molnupiravir (105 countries) and Nirmatrelvir (~95 countries). For Nirmatrelvir, SMS is one of only three API companies licensed alongside Divi's.
- Current activity: The company is taking validation batches and talking to other MPP licensees who hold finished-formulation licenses to supply sample quantities. It will probably apply for WHO pre-qualification afterward and is keeping decent stocks to qualify with as many licensees as possible.
- The risk sits entirely with SMS: MPP provides no demand obligation and no inventory financing. Any revenue is an opportunistic bonus, and management stresses that COVID product sales are inherently unpredictable because a wave could suddenly gather momentum or not materialize at all.
Potluri: "So, again, see some of these products which are opportunistic in nature so it is very difficult to predict, because you suddenly could expect an unexpected wave and suddenly the wave could, suddenly gather some good momentum and the product sales could go high."
Margins, Costs & The Industry Squeeze
- Industry-wide pressure: Margins across the industry reduced due to Chinese lockdowns causing raw material shortages and price increases, the war driving solvent and petroleum product costs up multifold, and logistics costs rising significantly. Regular annual erosion from new competitors added to the squeeze.
- SMS held up relatively well: FY22 gross margin improved to ~48% from ~40% in FY21, attributed to a thrust on own profit-making products versus lower-margin CMO and volume products. Management says market leadership, backward integration, and R&D mitigated the supply chain impact.
- The forward trade-off: Higher-volume products like ARV and Ibuprofen will pressure gross margins going forward; the company expects to maintain a 40–45% gross margin range with an EBITDA target above 22%.
- Interest costs rose: The company availed a GECL facility (government-backed liquidity window) to reduce working capital and keep funds ready for Ibuprofen and other products, which increased interest costs.
Potluri: "But our EBITDA target is definitely will be above 22%."
Associate Company: VKT Pharma
- ANDAs and commercial start: VKT Pharma received approval for six ANDA products (all non-ARV) at the end of February 2022, and commercials are just beginning. Launch quantities are being dispatched for most products.
- Revenue timeline: Full financial performance from VKT Pharma is expected in FY23/FY24, including own products and CMOs with large MNC companies. Full-scale revenue is expected in 2024.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| ARV revenue recovery | Return to earlier levels based on bids already awarded | By end of H1 FY23 |
| Ibuprofen capacity utilization | Reach 80–85% of installed capacity | By end of FY23 |
| Ibuprofen CEP approval | CEP approval expected | Next 1–2 months |
| Ibuprofen capacity expansion | Expand to 600–700 tonnes via CAPEX or debottlenecking | By end of FY23 |
| FY23 revenue growth | Minimum 25% growth over FY22 | FY23 |
| EBITDA margin | Above 22% | FY23 (implied) |
| Gross margin range | Maintain 40–45% | Going forward |
| Debt | No anticipated increase; normal expenditure from internal accruals | Next 1–2 years |
| Major CAPEX | No major expansion planned; consolidate existing products | Next 2 years |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Consolidated revenue (FY22) | ₹519.9 cr |
| Gross margin (FY22) | ~48%, up from ~40% in FY21 |
| EBITDA margin target | Above 22% going forward |
| Gross margin guidance | 40% to 45% range going forward |
| FY23 revenue growth target | Minimum 25% increase over FY22 |
| ARV revenue contribution | ~6–7% of revenue, down from ~40–45% (per an analyst's statement) |
| ARV revenue (9M FY22) | More than ₹200 cr in nine months; Q4 was hardly ₹6 cr (per an analyst's statement) |
| Ibuprofen installed capacity | 500 metric tonnes per month |
| Ibuprofen capacity utilization | 20%, up from 10% two months prior |
| Ibuprofen capacity utilization expected by FY23 end | 80% to 85% |
| Ibuprofen peak revenue expectation | ₹450 cr to ₹500 cr at full-scale operations |
| Ibuprofen current price | Around $9 range |
| Ibuprofen industry growth rate | Less than 5% |
| Sitagliptin API market size estimate | ₹400 cr to ₹500 cr at peak (Europe; U.S. expiry in 2024) |
| JV with Chemo revenue contribution | Around 5% to 8% of sales |
| Interest costs | Increased 69% YoY on yearly basis (per an analyst's statement) |
| CAPEX spent last year | ₹200 cr, mainly on Ibuprofen |
| VKT Pharma ANDA approvals | Six ANDAs approved end February 2022 |